Citius Pharmaceuticals, Inc. (CTXR) News
Filter CTXR News Items
CTXR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CTXR News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CTXR News From Around the Web
Below are the latest news stories about CITIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CTXR as an investment opportunity.
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesCitius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 743,496 shares of its common stock and accompanying warrants to purchase up to an aggregate of 743,496 shares of its common stock, at a purchase price of $4.035 per share and accompanying warrant in a |
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Management is focused on making LYMPHIR available to patients as quickly as possible, with preparations underway for launch in the first half |
Citius Oncology to explore strategic alternativesCitius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (CTXR), announced that it has retained Jefferies (JEF) as its exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value. The engagement of Jefferies underscores Citius Oncology’s commitment to exploring all avenues for enhancing its strategic positioning and advancing its mission to improve patient outcomes in oncology. Strategic alternatives under consideration ma |
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic AlternativesCitius Oncology, Inc. ("Citius Oncology" or "the Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value. |
Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral CapitalD. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which is close to commercializing Lymphir, an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma, the analyst tells investors in a research note. The firm believes that as Lymphir launches, it will become a value driver for its parent, Citius. Oncology drug Lymphir has achieved significant milestones in its develo |
American Air upgraded, Nordstrom downgraded: Wall Street's top analyst callsAmerican Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls |
Citius Pharma Reports 2024 Financial Results and Business UpdateCitius Pharma ( (CTXR) ) has released its Q4 earnings. Here is a breakdown of the information Citius Pharma presented to its investors. Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing first-in-class critical care products, with an emphasis on innovative therapies for unmet medical needs. It operates primarily in the pharmaceutical industry with a focus on oncology and infectious diseases. In its fiscal year 2024 financial report, Citius Pharm |
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business UpdateCitius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024. |
Market Sentiment Around Loss-Making Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)Citius Pharmaceuticals, Inc. ( NASDAQ:CTXR ) is possibly approaching a major achievement in its business, so we would... |
Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to ApprovalCitius Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that the Company held a constructive in-person Type C meeting with the U.S. Food and Drug Administration (FDA). The meeting followed successful completion of the Company's pivotal Phase 3 clinical trial of Mino-Lok®, a novel catheter lock solution designed to salvage central venous |